EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies

Eugenia Romano, Chantalle Moulton, Giulia Vanti, Lucia Grifoni, Giada Cremonesi, Lidia De Filippis, Anna Rita Bilia, Ennio Tasciotti

Pharmaceutics · 13.11.2026 · 18 (11) · 1472

DOI: 10.3390/pharmaceutics18111472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.11.2026. Verfasst von Eugenia Romano und 7 weiteren Autor:innen. Die Arbeit nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: #NEXTGENERATIONEU, Ministry of University and Research, Italian Ministry of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central nervous system (CNS) disorders remain difficult to treat because many pharmacologically active molecules do not achieve adequate exposure in the brain. The blood–brain barrier (BBB), blood-cerebrospinal fluid (CSF) barrier, efflux transporters, extracellular matrix, and local clearance mechanisms impose different constraints according to the target compartment and administration route. Nanocarriers can protect unstable payloads, alter pharmacokinetics, and support receptor-mediated or local delivery, but the same properties that promote transport can also increase immune recognition, tissue retention, and neurotoxicity. This review critically examines how nanoparticles (NPs) size, surface charge, composition, degradability, ligand density, and release kinetics should be matched to intravenous, intranasal, intrathecal, intracranial, and oral administration. Rather than treating these routes as interchangeable, we compare the barriers encountered by each route, the payloads for which it is best suited, and the experimental conditions that limit interpretation of reported brain uptake. Particular attention is given to the weak correspondence between many rodent efficacy studies and human delivery constraints, including protein-corona formation after systemic dosing, species differences in BBB and nasal anatomy, limited parenchymal penetration from cerebrospinal fluid, and the procedural risks of direct administration. The resulting route-specific framework is intended to support application-driven formulation design and more informative preclinical evaluation of CNS nanomedicines.

Förderung

  • #NEXTGENERATIONEU
  • Ministry of University and Research
  • Italian Ministry of Health

Zitieren

APA

Romano, E., Moulton, C., Vanti, G., Grifoni, L., Cremonesi, G., Filippis, L. D., Bilia, A. R., & Tasciotti, E. (2026). Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies. Pharmaceutics, 18(11), 1472. https://doi.org/10.3390/pharmaceutics18111472

Vancouver

Romano E, Moulton C, Vanti G, Grifoni L, Cremonesi G, Filippis LD, et al. Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies. Pharmaceutics. 2026;18(11):1472. doi:10.3390/pharmaceutics18111472

BibTeX
@article{Romano2026,
  author = {Romano, Eugenia and Moulton, Chantalle and Vanti, Giulia and Grifoni, Lucia and Cremonesi, Giada and Filippis, Lidia De and Bilia, Anna Rita and Tasciotti, Ennio},
  title = {Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1472},
  doi = {10.3390/pharmaceutics18111472}
}
Kostenlos starten →